A nutritional composition for use in enhancing one or more features or functions of the blood-brain barrier, including promoting healing or improved function of the blood-brain barrier. In certain embodiments, a method comprises administering to an individual in need thereof a nutritional composition comprises at least one human milk oligosaccharide as described herein to treat or prevent one or more blood-brain barrier related conditions.
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
2.
BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND SUPERMILD TRAUMATIC BRAIN INJURY
Disclosed herein are methods for aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild or a supermild traumatic brain injury.
Provided herein are compositions, systems, and methods for assessing and monitoring disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to hepatitis B virus infection.
The invention provides methods for determining whether a subject suspected of having a myocardial infarction is experiencing a Type I or Type II myocardial infarction. In particular, systems and methods are provided that employ a probability score based on decision tree based algorithms to process a subject's sex, age, and cardiac troponin concentration(s) and subject's galectin-3 (Gal-3) concentration.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The present disclosure relates to materials and methods for amplifying and detecting monkeypox virus in a sample, comprising a variety of combinations of amplification oligonucleotides and oligonucleotide probes. The disclosure also relates to oligonucleotide sequences, kits, and methods for detecting monkeypox virus.
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
A method of promoting healthy catch-up growth in a pediatric individual comprises administering a nutritional composition with an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric individual during a period of weight gain. A method also provides promoting healthy catch-up growth in an underweight individual by administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the individual.
Disclosed herein are methods and systems for determining whether at least one indeterminate pulmonary nodule identified in a subject is likely to be malignant or likely not to be malignant.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
8.
BOVINE MILK EXOSOMES FOR DELIVERING VITAMIN K2 AND INCREASING BIOAVAILABILITY
Bovine milk exosomes are loaded with vitamin K2. Nutritional compositions comprise the vitamin K2-loaded bovine milk exosomes and at least one of protein, fat and carbohydrate. A method for manufacturing vitamin K2-loaded bovine milk exosomes comprises mixing an aqueous solution of bovine milk exosomes with solubilized vitamin K2. A method of preparing a nutritional composition for providing improved bioavailability of vitamin K2 in vivo comprises adding bovine milk exosomes loaded with vitamin K2 to an aqueous solution which is added to a nutritional composition. A method also provides enhancing vitamin K2 bioavailability in vivo in a subject.
Disclosed herein are systems and assays that employ magnetically susceptible beads and point-of-care devices comprising magnetic immunosensors to determine the amount of glial fibrillary acidic protein (GFAP) in a biological sample obtained from a subject.
The present disclosure is directed to a bottle made of polyethylene terephthalate (PET) and having a circular cross-section. The bottle has a sidewall spanning between a neck finish and a base. The sidewall includes a shoulder portion and a panel portion, with the lower end of the shoulder portion and the upper end of the panel portion each sloping inward to create a waist. One or more circumferential ribs are positioned within the waist, and preferably at the trough of the waist. The one or more circumferential ribs are designed and configured to increase the hoop strength of the bottle, the vacuum stability of the bottle, or both.
Bifidobacterium animalisLactisLactis CECT 8145 (BPL1) and a carbohydrate blend to the individual. The carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch. A nutritional composition comprises protein, fat, the carbohydrate blend, and BPL1.
A method of increasing insulin sensitivity in a subject in need thereof comprises administering a nutritional composition comprising inositol, lysine, arginine, and beta-hydroxy-beta-methylbutyrate (HMB) to the subject. A nutritional composition comprises from about 0.01 to about 15 wt % HMB, from about 0.03 to about 40 wt % lysine, from about 0.02 to about 30 wt % arginine, and from about 0.01 to about 20 wt % inositol, all based on the weight of the nutritional composition.
A heat-treated, powdered nutritional composition comprises protein, fat, carbohydrate, and about 0.001 to about 5 wt % hesperidin, based on the weight of the powdered nutritional composition, wherein the weight ratio of (2S)-hesperidin to (2R)-hesperidin in the powdered nutritional composition is at least about 4:1. A process for manufacturing a heat-treated, powdered nutritional composition comprising hesperidin comprises providing an emulsified liquid nutritional composition comprising protein, fat, carbohydrate, and hesperidin, heat treating the emulsified liquid nutritional composition at a temperature of at least about 70ºC and not greater than about 105ºC for about 1 to about 30 seconds, and spray-drying the heat-treated liquid nutritional composition to form the powdered nutritional composition.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
14.
NUTRITIONAL COMPOSITIONS COMPRISING HUMAN MILK OLIGOSACCHARIDES AND BOVINE IMMUNOGLOBULIN
Disclosed are methods for treating or preventing infections in an individual and nutritional compositions for administering to individuals for the purpose of treating and/or preventing infections. The nutritional compositions include a combination of a human milk oligosaccharide and a protein ingredient having an enriched amount of one or more bovine immunoglobulin(s).
LATERAL FLOW METHODS, ASSAYS, AND DEVICES FOR DETECTING THE PRESENCE OR MEASURING THE AMOUNT OF UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 AND/OR GLIAL FIBRILLARY ACIDIC PROTEIN IN A SAMPLE
Disclosed herein are methods and devices for performing at least one lateral flow assay on a biological sample obtained from a subject to determine an amount or presence of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) alone, or an amount or presence of UCH-L1 and an amount or presence of glial fibrillary acidic protein (GFAP).
A method for promoting muscle regeneration in a subject comprises administering beta-hydroxy beta-methylbutyrate (HMB) and at least one citrus flavonoid to the subject.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
USE OF BIOMARKERS TO DETERMINE SUB-ACUTE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY (CT) SCAN THAT IS NEGATIVE FOR A TBI OR NO HEAD CT SCAN
Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
Disclosed herein are systems and methods for determining ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof in a blood sample obtained from a subject. Also disclosed herein are systems and methods for determining CK-MB, β-hCG, thyroid stimulating hormone (TSH), homocysteine, free thyroxine (free T4) or any combinations thereof in a blood sample.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
B32B 7/00 - Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical propert; Layered products characterised by the interconnection of layers
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones
USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI
Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
Sample analysis systems and methods using assay surfaces, assay processing units (APUs), assay processing systems (APSs), and laboratory systems are disclosed. An assay surface includes a sample processing component comprising a plurality of regions, including at least one wash region and at least one storage region configured to hold a plurality of solid supports moveable through the regions under a magnetic force, and a detection component configured to receive the solid supports. An APU includes an assay surface receiving component, a magnetic element configured to generate a moveable magnetic field, and one or more processors configured to move the magnetic field. An APS includes one or more assay surfaces and an APU. A laboratory system includes one or more APSs and a controller for parallel processing. Sample processing and detection methods are disclosed with a reduced sample volume and/or shortened processing time and/or higher sensitivity.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
21.
METHODS AND COMPOSITIONS FOR IMPROVING INSULIN PRODUCTION AND SECRETION
A method of improving insulin production in a subject suffering from impaired β-cell function comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject. A method of restoring and/or preserving β-cell mass in a subject suffering from impaired insulin production comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject. A method of delaying diabetes progression in a subject suffering from impaired insulin production comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject.
Disclosed herein are methods and systems of determining whether a subject's levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).
Disclosed herein are methods and systems of determining whether a subject's levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).
Disclosed herein are methods, kits, and systems for detecting or determining an amount, quantity, concentration and/or level of immunoglobulin G, subclass 4 (IgG4) in a biological sample from a subject. Particularly, the methods, kits and systems are directed to detection of IgG4 using an anti-IgG4 antibody that does not cross-react with other IgG subclasses.
A nutritional composition comprises HMB, arginine, glutamine, and an exosome-enriched product comprising intact bovine milk-derived exosomes. A method for improving wound healing in a subject comprises administering beta-hydroxy-beta-methylbutyrate (HMB), arginine, glutamine, and an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof. A method for improving wound healing in a subject comprises administering a nutritional composition comprising HMB, arginine, glutamine, and an exosome-enriched product comprising intact bovine milk-derived exosomes.
Provided herein are methods and nutritional compositions for treating gas in an individual. The nutritional compositions are useful for treating gas in an individual and include a mixture of human milk oligosaccharides and a probiotic blend of Bifidobacterium lactis, Bifidobacterium infantis, and Streptococcus thermophilus.
A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
27.
METHODS OF DIAGNOSING OR AIDING IN DIAGNOSIS OF BRAIN INJURY CAUSED BY ACOUSTIC ENERGY, ELECTROMAGNETIC ENERGY, AN OVER PRESSURIZATION WAVE, AND/OR BLAST WIND
Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI) by detecting levels of a biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject (e.g., a human subject) that has or may have sustained an injury or suspected injury to the head that is caused or believed to have been caused by acoustic energy, electromagnetic energy (e.g., from a sonic weapon, a directed energy weapon or a combination thereof), an over pressurization wave, blast wind, or any combination thereof.
Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a pediatric subject for traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a pediatric subject would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP, UCH-L1 or GFAP and UCH-L1.
Systems and methods for onboard pooling of samples for high-throughput analysis of the samples. Including a sample loading area for receiving a plurality of sample tubes, and a sample transport configured to continually transport individual vessels along a transport path from a sample dispense position to a sample capture and transfer position, with intermediate positions therebetween. At least one pipettor to transfer a first and second samples from the sample loading area to the sample transport and to pool the first sample and the second sample in a vessel on the sample transport to form a pooled sample. A sample transfer mechanism to capture at least a fractionated portion of the pooled sample from the vessel at the sample capture and transfer position and to transfer the at least a fractionated portion of the pooled sample for high-throughput analysis.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
30.
HIGH THROUGHPUT NUCLEIC ACID TESTING OF BIOLOGICAL SAMPLES
The presently disclosed subject matter relates to methods for rapid, sensitive, and high-throughput nucleic acid testing of biological samples, e.g., blood, serum, or plasma samples from donors, as well as systems capable of performing such high-throughput nucleic acid testing.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
31.
METHODS AND COMPOSITIONS FOR IMPROVING MUSCLE STRENGTH AND/OR REDUCING MUSCLE LOSS
A method for improving muscle strength and/or reducing muscle loss in a subject in need thereof comprises administering at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO, and optionally beta-hydroxy-beta-methylbutyrate (HMB) and optionally a plant flavonoid, to the subject. A nutritional composition comprises HMB and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, and, optionally, a plant flavonoid.
Liquid nutritional compositions comprise at least about 125 mg/ml of a protein system comprising, based on the weight of the protein system, less than 40 wt % micellar casein, greater than 15 wt % non-micellar casein, whey protein, whey protein hydrolysate, and partially hydrolyzed collagen. The liquid nutritional compositions further comprise at least about 5 mg/ml of β-hydroxy β-methylbutyrate (HMB), fat, and carbohydrate. The liquid nutritional compositions have a zero shear rate viscosity greater than 100 cp, an infinite shear rate viscosity of less than 200 cp, and a ratio of zero shear rate viscosity to infinite shear rate viscosity of greater than about 1.5.
A method for promoting wound healing in a subject comprises administering beta-hydroxy- beta-methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO to the subject in need thereof. A nutritional composition comprises HMB, arginine, glutamine, and an HMO selected from the group consisting of an acidic HMO and a neutral HMO.
Disclosed are methods of and nutritional compositions for treating or improving at least one marker of lung health in an individual. The nutritional compositions include a combination of a human milk oligosaccharide component and a designed lipid component.
A method of improving insulin production in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and beta-hydroxy-beta-methylbutyrate (HMB) to the subject. A method of improving insulin secretion in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and HMB to the subject. A nutritional composition comprises about 0.01 to about 15 wt % HMB, about 0.03 to about 40 wt % lysine, and about 0.02 to about 30 wt % arginine.
Systems, apparatuses and methods may provide technology that identifies minority class data and majority class data in patient-level data, wherein the minority class data corresponds to patients with a health failure and the majority class data corresponds to patients without the health failure, oversamples the minority class data to obtain synthetic class data and automatically reduces, via a machine learning classifier, a set of risk factor variables based on the majority class data, the minority class data and the synthetic class data.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Disclosed are methods for treating or preventing infections in an individual and nutritional compositions for administering to individuals for the purpose of treating and/or preventing infections. The nutritional compositions include a combination of a human milk oligosaccharide and a bovine immunoglobulin.
A method of for improving muscle energy production and/or muscle strength in a subject, and/or for reducing muscle loss in a subject comprises administering beta-hydroxy beta-methylbutyrate (HMB) and at least one citrus flavonoid to the subject. A nutritional composition comprises protein, fat, carbohydrate, HMB, and at least one citrus flavonoid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
39.
SEQUENCE CONVERSION AND SIGNAL AMPLIFIER DNA HAVING ABASIC NUCLEIC ACIDS, AND DETECTION METHODS USING SAME
Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide that includes, in the 5' to 3' direction, a signal DNA generation sequence, an endonuclease recognition site, and a complementary sequence that has at least one abasic moiety and wherein the complementary sequence has a first complementary sequence that is complementary to at least a portion of the signal DNA generation sequence and a second complementary sequence that is complementary to the 3' end of the target nucleic acid. Also disclosed are methods that include a second oligonucleotide including, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide and that optionally has at least one abasic site.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
40.
METHODS FOR ENHANCING MUSCLE PERFORMANCE OR REDUCING CHRONIC FATIGUE BY ADMINISTERING BOVINE MILK-DERIVED EXOSOMES
A method of enhancing muscle performance in a subject in need of improved physical performance comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof. A method of reducing chronic fatigue in a subject recovering or recovered from a viral infection comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject.
A method of improving joint health in a subject in need thereof comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
42.
IMPROVED METHODS, REAGENTS AND KITS FOR DETERGENT-BASED INACTIVATION OF BETACORONAVIRUS PRIOR TO AND/OR WHILE ASSESSING A BIOLOGICAL SAMPLE FOR SARS-COV-2 ANTIGEN OR ANTIBODY
Disclosed herein are methods of inactivating any ß-coronaviruses (e.g., SARS-CoV or SARS-CoV-2) in a biological sample prior to testing the sample for the presence of a ß-coronavirus (e.g., SARS-CoV or SARS-CoV-2) antigen or antibody, which involves maintaining the sample in a medium comprising at least one non-ionic surfactant. The at least one non-ionic surfactant inactivates the ß-coronavirus (e.g., SARS-CoV or SARS-CoV-2) as determined by an inability of the ß-coronavirus (e.g., SARS-CoV or SARS-CoV-2) to replicate in culture.
Disclosed herein are methods, kits, and systems for detecting at least one type of SARS-CoV-2 antigen and at least one type of anti-SARS-CoV-2 antibody in a subject, which comprises the use of at least two different types of microparticle reagents for binding at least one type of SARS-CoV-2 antigen and at least one type of anti-SARS-CoV-2 antibody and at least two different types of detection reagents for binding each of the microparticle reagents.
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
44.
USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI
Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
A method of forming a heat-treated liquid nutritional composition having a neutral pH and comprising a water-insoluble plant flavonoid comprises providing an aqueous liquid nutritional composition having a pH of from about 6 to about 7.5 and comprising protein, fat, carbohydrate, and water-insoluble plant flavonoid, homogenizing the liquid nutritional composition at a pressure of at least about 2000 psi, and heat treating the liquid nutritional composition. A heat-treated liquid nutritional composition having a pH of from about 6 to about 7.5 comprises a water-insoluble plant flavonoid, protein, fat and carbohydrate. At least about 75 wt % of the water-insoluble plant flavonoid remains suspended throughout the liquid nutritional composition after two months of storage at room temperature.
A method of increasing height in a pediatric subject comprises enterally administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric subject in need thereof. A method of promoting linear bone growth in a pediatric subject comprises enterally administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric subject in need thereof. A method of obtaining an exosome-enriched product from cheese whey comprises subjecting the cheese whey to microfiltration (MF), ultrafiltration (UF), and diafiltration (DF) steps, wherein the MF, UF, and DF steps employ, successively, membranes with cut off values which gradually decrease in size with each filtration step, wherein the cheese whey is sweet cheese whey and has a pH from about 6.0 to about 6.5.
A23C 9/142 - Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
A23L 33/115 - Fatty acids or derivatives thereof; Fats or oils
A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
A container (100) having a main body (104) including one or more sidewalls (106) having an interior surface (120) and an exterior surface (122) and defining an interior compartment (108), the one or more sidewalls having an upper portion (114) defining a circular opening (110) to the interior compartment and an annular flange (128) extending from the exterior surface and a lid-collar assembly (112, 116) comprising a lid (116) attached to a collar (112) affixed to the main body, the collar having an inner side surface (162) positioned radially outward of the annular flange and a plurality of longitudinally extending ribs (210) spaced apart on the inner side surface, wherein the plurality of ribs engage the annular flange to resist rotation of the lid-collar assembly relative to the main body.
Disclosed herein are methods, kits, and systems relates for detecting the presence or determining the amount of SARS-CoV-2 nucleocapsid protein in one or more samples obtained from a subject.
A method of preventing, reducing, or delaying the onset of fatty liver disease in a subject comprises enterally administering intact bovine milk-derived exosomes consisting of endogenous cargo to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the intact bovine milk-derived exosomes consisting of endogenous cargo can be administered in an amount effective to reduce de novo lipogenesis in the subject. The intact bovine milk-derived exosomes consisting of endogenous cargo can be administered to the subject directly or in a nutritional composition.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
51.
METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASE
A method of reducing or delaying the onset of fatty liver disease in a subject comprises enterally administering at least one human milk oligosaccharide (HMO) to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the at least one HMO is administered in an amount effective to reduce de novo lipogenesis in the subject. The at least one HMO can be administered to the subject directly or in a nutritional composition.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61L 33/12 - Polypeptides, proteins or derivatives thereof
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Digital pass verification systems and methods are disclosed herein. An example non-transitory computer readable medium includes instructions that, when executed, cause a processor to at least: verify a flight reservation of a person; check a test record of the person associated with the flight reservation, the test record associated with a diagnostic test for an analyte of interest; and display a first interface when the test record indicates the person tested negative for the analyte of interest and display a second interface when the test record indicates the person tested positive for the analyte of interest.
H04W 12/30 - Security of mobile devices; Security of mobile applications
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/65 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records stored on portable record carriers, e.g. on smartcards, RFID tags or CD
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
At least a portion of fabrics (404) for use in medical devices (10, 100, 2000) is formed from polymeric materials. The fabrics may be uncoated, partially coated or fully coated with one or more layers (402) of a polymer. The fabrics may be used for the leaflets (108) and/or cuffs (106) of prosthetic heart valves (100) and as a component of other medical devices (2000).
A stabilized fabric composed of a mesh or a woven fabric is disclosed as are methods of their manufacture, the manufacture of medical devices made using a stabilized fibers and stabilized medical devices are all disclosed. Fabrics can be stabilized by several techniques including: using mechanical, chemical and/or energetic fasteners at warp and weft intersections in the weave; by using various weaving techniques and fibers. Meshes can be stabilized when properly dimensioned and arranged junctions and struts of the necessary properties are used. All of these stabilized fabrics can be made of synthetic polymer materials such as ultrahigh molecular weight PE or PP and expanded PTFE.
Sample analysis systems and methods using assay surfaces, assay processing units (APUs), assay processing systems (APSs), and laboratory systems are disclosed. An assay surface includes a sample processing component comprising a plurality of regions, including at least one wash region and at least one storage region configured to hold a plurality of solid supports moveable through the regions under a magnetic force, and a detection component configured to receive the solid supports. An APU includes an assay surface receiving component, a magnetic element configured to generate a moveable magnetic field, and one or more processors configured to move the magnetic field. An APS includes one or more assay surfaces and an APU. A laboratory system includes one or more APSs and a controller for parallel processing. Sample processing and detection methods are disclosed with a reduced sample volume and/or shortened processing time and/or higher sensitivity.
Methods of decreasing muscle atrophy and/or promoting muscle regeneration in a subject at risk of muscle atrophy comprise orally administering a nutritional composition comprising at least one of protein, fat and carbohydrate, and bovine milk-isolated exosomes comprising intact exosomes. In specific embodiments, the subject suffers from malnutrition, acquired immune deficiency syndrome (AIDS), cancer, diabetes, chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), non-alcoholic fatty liver disease (NAFLD), or a burn injury, or has undergone clinical corticosteroid treatment.
Methods of increasing microvascular blood flow in the muscle of a human subject comprise orally administering about 100 to about 800 mg cocoa flavanols per day in a nutritional composition comprising at least one source of protein, to a subject in need of increased microvascular blood flow in the muscle.
Disclosed herein are methods, complexes, kits, systems and algorithms for detecting or determining an amount, quantity, concentration and/or level of at least one type of anti-β-coronavirus antibody, such as, for example, an anti-SARS-CoV antibody or anti-SARS-CoV-2 antibody (including an IgA, IgG and/or an IgM antibody), in one or more samples obtained from a subject.
Disclosed herein are methods, kits, systems, algorithms and improvements for detecting the presence of or determining an amount, quantity, concentration and/or level of an antibody against at least one type of β-coronavirus, such as, for example, an antibody against SARS-CoV or SARS-CoV-2, in one or more samples obtained from a subject. In some aspects, the methods, kits and systems relate to detecting the presence of or determining an amount, quantity, concentration and/or level of at least one type of anti-β-coronavirus antibody, such as an IgG and/or IgM antibody, in one or more samples obtained from a subject. The methods, kits systems, algorithms and improvements can also be used to monitor a subject's response and/or treatment to a β-coronavirus, determine whether or not a subject will develop or experience a cytokine storm, predict outcome in a subject, determine whether a subject can be administered a vaccine for a β-coronavirus, monitoring antibody response in individuals that have received a β-coronavirus vaccine (such as a SARS-CoV-2 vaccine), and/or determine the immune status of a subject.
Disclosed are compositions, including nutritional compositions, for reducing illness/infection related symptoms. In particular, administration of the inventive compositions helps to reduce symptoms such as those selected from impaired cognition, fever, anhedonia, loss of appetite, hyperalgesia, and sleep disturbances, lethargy, chills, irritability, and skin hypersensitivity to touch that often result from respiratory virus-induced inflammation.
A method of obtaining an exosome-enriched product comprises providing a whey-containing bovine milk fraction, conducting a first centrifugation of the whey-containing bovine milk fraction to obtain a whey middle fraction, conducting a second centrifugation of the whey middle fraction at an increased speed to obtain a concentrated whey fraction, filtering the concentrated whey fraction to obtain a filtered whey fraction, and conducting a third centrifugation of the filtered whey fraction at a further increased speed to obtain an exosome-enriched product. The exosome-enriched product comprises intact exosomes and less than 5 wt% casein based on the total weight of protein in the exosome-enriched product. Nutritional compositions comprise protein, carbohydrate, and/or fat, and exosomes provided by addition of the exosome-enriched product. A method of improving insulin sensitivity in a subject comprises administering a nutritional composition comprising the exosome-enriched product.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
KATHOLIEKE UNIVERSITEIT LEUVEN KU LEUVEN RESEARCH & DEVELOPMENT (Belgium)
Inventor
Leirs, Karen
Pérez-Ruiz, Elena
Lammertyn, Jeroen
Abstract
Provided herein is a method of loading wells with a liquid droplet, or a portion thereof, wherein each liquid droplet comprises solid supports and a detergent or surfactant, such that the detergent or surfactant reduces the contact angle between the liquid droplet and the wells. Also provided is a method of detecting and quantifying an analyte of interest in a sample, which involves loading wells in an array with a liquid droplet according to aforementioned method, wherein the liquid droplet comprises an analyte captured on a solid support.
A method of treating diarrhea or an inflammatory condition of the gut in a subject comprises administering a therapeutically effective amount of beta-hydroxy-beta-methylbutyrate (HMB) or a salt thereof to a subject in need thereof. A method of treating secretory diarrhea in a subject comprises administering a therapeutically effective amount of HMB or a salt thereof to a subject exhibiting one or more of the following symptoms: loss of fluids from the gut, loss of electrolytes from the gut, dehydration, or inflammation of the intestinal tract.
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A method of promoting bone health in a moderately malnourished individual is provided. The method includes treating the moderately malnourished individual with a nutritional composition that contains a carbohydrate blend. The carbohydrate blend includes a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Provided herein are compositions, methods, and kits for amplifying and detecting human bunyaviruses. In certain embodiments, provided herein are bunyavirus specific nucleic acid probes and primers, and methods for detecting bunyavirus nucleic acid.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
67.
COMPOSITIONS AND METHODS FOR DETECTING PICOBIRNAVIRUS
Provided herein are compositions, methods, and kits for detecting human picobirnavirus (PBV). In certain embodiments, provided herein are PBV specific nucleic acid probes and primers, and methods for detecting PBV nucleic acid.
C07K 14/085 - Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
68.
NUTRITIONAL COMPOSITIONS FOR TREATING A CLOSTRIDIUM DIFFICILE INFECTION
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A23L 33/125 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing starch hydrolysates
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/718 - Starch or degraded starch, e.g. amylose, amylopectin
A23L 29/25 - Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
69.
BOVINE MILK-ISOLATED POWDERED EXOSOMES, NUTRITIONAL COMPOSITIONS AND METHODS
Bovine milk-isolated powdered exosomes comprise intact exosomes. Nutritional compositions comprise protein, carbohydrate, and/or fat, and exosomes isolated from bovine milk. A method of preparing powdered exosomes comprises centrifuging bovine milk to form a lipid fraction top layer, a whey fraction middle layer, and a first pellet of cells and debris, separating the whey fraction and centrifuging the separated whey fraction to remove additional fat, casein aggregates and debris and form a substantially clear whey fraction, microfiltering the substantially clear whey fraction to remove residual debris, centrifuging the microfiltered whey fraction to obtain a pellet containing exosomes, incubating the exosome-containing pellet in aqueous medium to dissolve the pellet without disrupting exosome membranes to provide an exosome suspension, and drying the suspension to obtain the powdered exosomes. Methods of lowering a risk of developing, or treating, insulin resistance, prediabetes, or diabetes in a subject employ exosomes isolated from bovine milk.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
At least a portion of sheet materials (400) for use in medical devices (10, 100, 2000) is formed from polymeric materials. The sheet materials may be partially coated or fully coated with one or more additional layers (402, 404) of a polymer. The sheet materials may be used for the leaflets (108) and/or cuffs (106) of prosthetic heart valves and as a component of other medical devices.
in vivo in vivo sensor. The protein switch can be used to determine a level of an analyte that is diagnostic for health and/or well-being of a subject.
A plastic container (10) having an upper portion (16) including a reclosable and resealable open top end (18), a base portion (24) closing off an end of the container, and an intermediate portion (22) being integrally formed with and exiting from the upper portion to the base portion. The intermediate portion includes by a plurality of horizontal ribs (42) arranged substantially perpendicular to a longitudinal axis of the container, at least one of the horizontal ribs being disposed longitudinally between an upper land and a lower land. The container has a volume capacity is 235 ml. or greater and a plastic weight of 20 g or less. At least one of the plurality of horizontal ribs has a horizontal rib depth (DR) of at least 4.5 mm and a horizontal rib width (WR) to horizontal rib depth ratio of between 2.2 to 2.7.
Plant-based nutritional compositions comprise fava bean protein isolate and pea protein. The fava bean protein isolate comprises greater than about 10 wt% of the total protein in the composition, and the pea protein comprises less than about 50 wt% of the total protein in the composition. In certain embodiments, the nutritional compositions are high in protein, high in fiber, and low in calories. The compositions may be dairy-free and/or soy-free.
Processes for preparing a powdered nutritional composition comprise dry blending protein, fat, and carbohydrate, micronizing the resultant mixture to provide 99% of particles with a size less than about 50 micrometers, and agglomerating the micronized powder to form agglomerates. Powdered nutritional compositions are produced by the processes of dry blending, micronizing, and agglomerating.
The disclosure provides kits and methods for detecting a substance that interferes with detection of an analyte in a sample and for expanding the dynamic range and reducing the hook effect of an immunoassay. The kits and methods employ two conjugates with two different detectable labels, at least one of which is a chemiluminescent compound of Formula (I).
Disclosed herein are compounds, conjugates, and methods that may be used to detect the presence of an analyte in a sample, such as a biological sample.
C09B 23/04 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups one CH group, e.g. cyanines, isocyanines, pseudocyanines
C09B 23/06 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups three CH groups, e.g. carbocyanines
A nutritional ingredient for use in nutritional powders is provided. The nutritional ingredient is an agglomerated calcium source, which includes particles of a calcium source adhered together with a lecithin binder. The nutritional ingredient functions as both a flow agent and an antifoam agent when incorporated into nutritional powders, such as powdered infant formulas.
System for storing and dispensing liquid in a digital microfluidic chip includes a plurality of reservoir electrodes defining a reservoir having an outlet and a first end opposite the outlet, the reservoir configured to be in fluidic communication with at least one device electrode proximate the outlet, the at least one device electrode and at least one of the plurality of reservoir electrodes configured to generate electrical actuation forces to dispense at least one droplet from the reservoir through the outlet. The plurality of reservoir electrodes include a first reservoir electrode proximate the first end, a reservoir outlet electrode proximate the outlet, and at least one intermediate reservoir electrode disposed between the first electrode and the reservoir outlet electrode. The first reservoir electrode, the reservoir outlet electrode, and the at least one intermediate reservoir electrode each has an electrode surface area in plan view greater than or equal to an electrode surface area of each of the at least one device electrodes.
Digital microfluidic device includes a first substrate and a second substrate aligned generally parallel to each other with a gap defined therebetween in side view. At least one of the first substrate and the second substrate include a first electrode array, a second electrode array spaced from and in electrical communication with the first electrode array, and a first interstitial area defined between the first electrode array and the second electrode array. At least one of the first electrode array and the second electrode array is configured to generate electrical actuation forces within an actuation area to urge at least one droplet within the gap along the at least one of the first substrate and the second substrate. At least one spacer is disposed in the first interstitial area to maintain the gap between the first substrate and the second substrate.
Digital microfluidic and analyte detection device includes a first substrate and a second substrate aligned generally parallel to each other with a gap defined therebetween in side view. At least one of the first and second substrates has an electrode array configured to generate electrical actuation forces to urge at least one droplet within the gap along the at least one of the first substrate and the second substrate. The electrode array has a plurality of electrodes defining an electrode array area in plan view. At least one of the first substrate and the second substrate has a well array defining a well array area in plan view. The well array area is bounded within the electrode array area and overlapping a portion of each of the plurality of electrodes. The well array area overlaps less than 75% of the electrode array area in plan view.
EVALUATING BIOMARKERS ALONG WITH ADVANCED MAGNETIC RESONANCE IMAGING PROCEDURES IN A HUMAN SUBJECT THAT HAS SUSTAINED OR MAY HAVE SUSTAINED A HEAD INJURY
Disclosed herein are methods that aid in the determination of whether to perform one or more advanced magnetic resonance imaging (MRI) procedures for a head injury by determining the presence or amount of one or more biomarkers in a sample obtained from the human subject. Also disclosed are methods of aiding in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, e.g., by assessing biomarker levels in combination with advanced MRI procedures. Further, also disclosed are methods of predicting or aiding in the prediction of the outcome of human subjects that have suffered a traumatic brain injury (TBI) as well as determining the course of treatment or efficacy of a course of treatment for a human subject who has suffered a TBI, e.g., by assessing biomarker levels in combination with advanced MRI procedures.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
82.
METHODS FOR PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS WITH CORONARY ARTERY DISEASE
The present disclosure relates to methods for predicting or determining whether a subject with coronary artery disease is likely to experience or develop a major adverse cardiovascular event (MACE) based on comparing the concentration or levels of cardiac troponin I (cTnI) determined by one or more assays before a stress test and then during or after a stress test.
The disclosure provides methods of analyzing an analyte of interest in a biological sample using fluorescent agents and macroconjugates which comprise a core containing a cross-linked polymer or protein, tags, specific binding members or fragments thereof, and optionally carrier proteins. Also provided are methods of analyzing two or more analytes of interest in a biological sample in a single assay using microparticles and detection conjugates comprising different fluorophore labels, acquiring transmitted light and fluorescent images of the microparticles, and using a customized image analysis process to analyze the acquired images.
At least a portion of fabrics for use in medical devices is formed from polymeric materials. The fabrics may be uncoated, partially coated or fully coated with one or more layers of a polymer. The fabrics may be used for the leaflets and/or cuffs of prosthetic heart valves and as a component of other medical devices.
A method of promoting healthy catch-up growth in a moderately malnourished individual is provided. The method includes administering to the moderately malnourished individual a nutritional composition that contains a carbohydrate blend, wherein the carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.
The disclosure provides a method for an enhanced detection of an analyte present in a biological sample. After the formation of the analyte/specific binding member(s)/detectable label complex, the labels are eluted and a first aliquot of eluant is brought into contact with a solid support, wherein the solid support comprises immobilized thereto specific binding member that specifically binds to the label, removing the first aliquot from the solid support and contacting the solid support with a second aliquot of the eluted label, and repeating the above steps, such that the label is concentrated on the solid support for further analysis to quantify the analyte in the biological sample.
Provided herein are compositions, systems, and methods for assessing and monitory disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to disease therapies (e.g., in HBV infection).
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A package (5) is disclosed for holding a powdered material. The package (5) comprises a container (10) and a scoop (50). The container (10) comprises a main body (20), a first hinged closure (30), and a second hinged closure (40). The main body (20) may optionally comprise a collar (325). The first hinged closure (30) is configured to fully cover and resealably close the main body (20) of the container (10) when the container (10) is not in use. The first hinged closure (30) may comprise a pocket (33) to receive the bowl (52) of the scoop (50). Alternatively, the second hinged closure (40) may comprise a scoop receiving structure (344) to secure a scoop (50). The second hinged closure (40) covers at least a portion of the first hinged closure (30) when the container (10) is not in use, thereby keeping the scoop (50) clean between uses.
A nutritional powder composition comprises from about 0.1 to about 3.0 wt % beta-hydroxy-beta-methylbutyrate (HMB), and from about 10 to about 25 wt % of a protein system, based on the weight of the powder composition. The protein system comprises from about 20 to about 60 wt % sodium caseinate, from 0 to about 30 wt % whey protein, from about 5 to about 25 wt % intact soy protein, and from about 15 to about 60 wt % hydrolyzed soy protein, based on the weight of the protein system. All or a portion of the sodium caseinate in the protein system may be replaced with potassium caseinate, and/or all or a portion of the intact soy protein may be replaced with intact pea protein, and/or all or a portion of the hydrolyzed soy protein may be replaced with hydrolyzed pea protein.
Aqueous lipid emulsions for providing enteral nutrition are provided. The aqueous lipid emulsions include at least 33% of lipids, lipid soluble nutrients, or a combination thereof, based upon the total weight of the emulsion, and are essentially free of carbohydrate and protein. The aqueous lipid emulsions are shelf-stable for at least 7 months. The aqueous lipid emulsions are a source of supplemental enteral nutrition for any patient in need thereof, including preterm infants.
A23D 7/005 - Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
A23L 33/00 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
A tube feeding composition includes from about 20 wt% to about 40 wt% of fruit and vegetable, at least 3 wt% of whole grain, a source of protein, a source of carbohydrate, and a fat. The tube feeding composition has a desirable viscosity profile for tube feeding applications and may be manufactured using at least two homogenization steps.
The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
93.
METHODS FOR AIDING IN THE DIAGNOSIS AND EVALUATION OF A SUBJECT WHO HAS SUSTAINED AN ORTHOPEDIC INJURY AND THAT HAS OR MAY HAVE SUSTAINED AN INJURY TO THE HEAD, SUCH AS MILD TRAUMATIC BRAIN INJURY (TBI), USING GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND/OR UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 (UCH-L1)
Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
A sterilized liquid nutritional composition has an off-white color and a pH of from about 6 to 7.5 and comprises a source of protein, a source of fat, a source of carbohydrate, green tea extract comprising epigallocatechin gallate (EGCg), and an insoluble source of iron comprising at least one of ferric orthophosphate and ferric pyrophosphate. The liquid nutritional composition comprises, per 237 ml serving, from about 50 to 500 mg green tea extract and from about 6 to 60 mg ferric orthophosphate and/or ferric pyrophosphate, and has a Hunter L value not less than 60.
Nutritional tablets and methods of making nutritional tablets are provided. The nutritional tablets include a compressed nutritional powder that includes protein, carbohydrate, fat, and 0.15% to 6% by weight of a flow agent based on the weight of the nutritional tablet. The nutritional tablet has a hardness of no more than 14 N and a surface polarity of greater than 30.5%.
Nutritional compositions for modulating or reducing inflammation in an individual in need. The nutritional compositions can include a rice protein hydrolysate having a minimum degree of hydrolysis of 15%, where at least 30% of the rice protein hydrolysate peptides are less than 1000 Da., and no more than 30% of the rice protein peptides are greater than 3000 Da.
Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.
Disclosed are nutritional compositions including 2'-fucosyllactose (2'-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.
patents
